iRhythm Holdings, Inc. Stock: price and insider trades · United States

From a competitive standpoint, iRhythm holds a differentiated position in the ambulatory ECG market. Its edge is built on a large body of real-world clinical evidence, the convenience of a patch-based form factor, automated data processing, and a long operating history in long-term continuous monitoring. The company competes against other cardiac diagnostics providers, traditional Holter manufacturers, and broader medtech players, but its recurring emphasis on clinical utility and patient adherence supports a strong brand in its niche. The Zio platform is often positioned as a superior alternative to short-duration monitoring when intermittent events are suspected.

Geographically, iRhythm still derives most of its business from the United States, while also expanding internationally. A notable recent milestone was the launch of the Zio Long-Term Continuous Monitoring service in Japan in 2025, marking an important step in its overseas commercialization strategy. More recently, iRhythm has continued to publish and present data at major medical congresses in 2025 and 2026, while also announcing an AI collaboration with Lucem Health and reporting progress toward improved operating leverage and cash generation. For investors, iRhythm is best viewed as a growth-oriented healthcare technology company with exposure to reimbursement dynamics, clinical adoption trends, and the continued shift toward longer-duration, AI-enabled cardiac diagnostics.